Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 43

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 43
---
, development
and commercialization objectives.

To induce valuable employees
to remain at our Company, in addition to salary and cash incentives, we provide share incentive grants that vest over time. The value
to employees of these equity grants that vest over time may be significantly affected by movements in the price of our Class A Ordinary
Shares that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although
we have appointment letters with our key employees, any of our employees could resign at any time, with 1-month to 3-months prior written
notice or with payment in lieu of notice.

Recruiting and retaining qualified
officers, scientific, clinical, sales and marketing personnel or consultants will also be critical to our success. In addition, we rely
on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and preclinical studies
development and commercialization strategy. The loss of the services of our executive officers or other key employees and consultants
could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully
implement our business strategy.

Furthermore, replacing executive
officers and key employees or consultants may be difficult and may take an extended period of time, because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize
drug and diagnostics technology candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train,
retain or motivate these key personnel or consultants on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel.

We also experience competition
for the hiring of scientific and clinical personnel from universities and research institutions. Our consultants and advisors may be employed
by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability
to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

We will need to increase the size and capabilities
of our organization, and we may experience difficulties in managing our growth.

As of the date of this annual
report, we have 1 full-time employees. Of these, 1 full-time are engaged in general and administrative functions. As of the date of this
annual report, all our employees are located in Asia. In addition, we have engaged and may continue to engage 10 independent